LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) have earned an average rating of “Moderate Buy” from the eight brokerages that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $45.60.

LENZ has been the subject of a number of analyst reports. Wall Street Zen lowered LENZ Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Citigroup dropped their target price on LENZ Therapeutics from $52.00 to $26.00 and set a “buy” rating on the stock in a report on Thursday. Weiss Ratings restated a “sell (d-)” rating on shares of LENZ Therapeutics in a report on Thursday, January 22nd. William Blair reaffirmed an “outperform” rating on shares of LENZ Therapeutics in a research report on Tuesday, March 10th. Finally, HC Wainwright reiterated a “buy” rating on shares of LENZ Therapeutics in a research note on Monday, December 15th.

Institutional Investors Weigh In On LENZ Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in LENZ. Versant Venture Management LLC bought a new position in LENZ Therapeutics in the 3rd quarter valued at approximately $123,758,000. UBS Group AG increased its holdings in shares of LENZ Therapeutics by 30.8% in the 4th quarter. UBS Group AG now owns 1,571,738 shares of the company’s stock worth $25,148,000 after purchasing an additional 370,122 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of LENZ Therapeutics by 3.0% in the third quarter. Vanguard Group Inc. now owns 1,330,286 shares of the company’s stock worth $61,965,000 after purchasing an additional 39,292 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its holdings in shares of LENZ Therapeutics by 108.8% during the second quarter. Adage Capital Partners GP L.L.C. now owns 1,122,738 shares of the company’s stock valued at $32,907,000 after purchasing an additional 585,000 shares in the last quarter. Finally, Franklin Resources Inc. lifted its holdings in shares of LENZ Therapeutics by 86.7% during the fourth quarter. Franklin Resources Inc. now owns 1,096,334 shares of the company’s stock valued at $17,541,000 after purchasing an additional 509,250 shares in the last quarter. Institutional investors own 54.32% of the company’s stock.

LENZ Therapeutics Price Performance

NASDAQ:LENZ traded down $0.08 during mid-day trading on Friday, hitting $8.87. 243,645 shares of the company’s stock were exchanged, compared to its average volume of 1,052,921. The company has a market cap of $277.92 million, a PE ratio of -3.18 and a beta of 0.52. LENZ Therapeutics has a one year low of $8.56 and a one year high of $50.40. The business has a fifty day moving average price of $13.95 and a 200 day moving average price of $24.30.

LENZ Therapeutics (NASDAQ:LENZ) last announced its earnings results on Tuesday, March 24th. The company reported ($1.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.25). The business had revenue of $1.59 million for the quarter, compared to analyst estimates of $3.09 million. On average, equities analysts forecast that LENZ Therapeutics will post -2.18 EPS for the current fiscal year.

Key Stories Impacting LENZ Therapeutics

Here are the key news stories impacting LENZ Therapeutics this week:

• Positive Sentiment: HC Wainwright trimmed several near-term loss estimates (Q1 2026 to ($0.86) from ($0.96); Q2 2026 to ($0.77) from ($0.83)) and raised FY2026 and FY2027 estimates (FY2026 to ($2.68) from ($2.77); FY2027 to ($0.61) from ($0.72)). The firm kept a “Buy” rating, signaling continued analyst conviction despite ongoing losses.
• Positive Sentiment: HC Wainwright also lifted certain forward-year expectations (including FY2030 EPS of $3.18), suggesting the analyst sees longer-term upside from LENZ’s pipeline, which supports a constructive view for growth-stage investors.
• Neutral Sentiment: Bank of America posted a new $29 price target for LENZ, providing a mid-range analyst target that implies meaningful upside vs. the current price but is well below some prior peak targets. Read More.
• Neutral Sentiment: Recent company disclosures and the Q4 2025 earnings call/transcript remain active reference points for investors evaluating execution and guidance after a revenue and EPS miss last quarter. See the earnings summary and transcript for details. Read More. • Read More.
• Negative Sentiment: Citigroup cut its price target sharply from $52 to $26 while maintaining a “Buy” rating — the halving of the target is a negative signal that reduces the implied upside from prior expectations and can pressure the stock. Read More.
• Negative Sentiment: HC Wainwright also issued some downward revisions to longer-term estimates (FY2028 to $0.62 from $0.65; FY2029 to $1.71 from $1.84) and worsened its Q4 2026 EPS view (to ($0.48) from ($0.41)), highlighting continued uncertainty in later-year profitability projections.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.